5 big biotech losers from JPMorgan's massive healthcare conference

Advertisement
5 big biotech losers from JPMorgan's massive healthcare conference

San Francisco Rain

Advertisement

The J.P. Morgan Healthcare Conference in San Francisco is a chance for healthcare companies to start the year off right.

Executives give high-stakes presentations to investors - and then meet with them privately - to try to convince them to invest in their companies. Often, companies will save up news to announce at the event, like clinical trial results that show a new drug is working, or good financial news.

But sometimes, the news is disappointing. That can send stocks plummeting and turn off investors. Or it can create openings for savvy investors to bet on companies at a cheap price.

These are the five biotech stocks that had big tumbles during the conference this week.

Advertisement

Happy hunting.

Subscribe to Business Insider's weekly healthcare newsletter Dispensed for all the biggest news from the J.P. Morgan Healthcare Conference.

{{}}

Alder BioPharmaceuticals

Alder BioPharmaceuticals

Ticker: ALDR

Share drop: -8.2% on January 8

What happened: Alder is working on a type of migraine-prevention drug known as a CGRP inhibitor. The company presented at the JPMorgan conference on January 8. You can see the company's presentation here.

Dova Pharmaceuticals

Dova Pharmaceuticals

Ticker: DOVA

Share drop: -10% on January 8

What happened: Dova sells a treatment for the blood disease known as thrombocytopenia. The company presented at the J.P. Morgan Healthcare Conference on January 8, and discussed additional potential markets for its treament. You can see the presentation here.

Advertisement

Crinetics Pharmaceuticals

Crinetics Pharmaceuticals

Ticker: CRNX

Share drop: -7.1% on January 10

What happened: Crinetics is working on treatments for endocrine diseases and tumors. The company presented at the J.P. Morgan Healthcare Conference on January 9, after the close of regular trading. You can see Crinetics's slides from the event here.

Rubius Therapeutics

Rubius Therapeutics

Ticker: RUBY

Share drop: Rubius lost 8.1% on January 7, and another 8.6% on January 8.

What happened: Rubius presented at the J.P. Morgan Healthcare Conference on January 7, and provided an update on its 2019 plans. You can see the slides from the company's presentation here.

Advertisement

Sangamo Therapeutics

Sangamo Therapeutics

Ticker: SGMO

Share drop: -14% on Wednesday, January 9.

What happened: Sangamo tumbled on the day it presented at the J.P. Morgan Healthcare Conference. The company aims to use gene therapies to treat diseases like hemophilia and sickle cell. It told investors to expect some updates on two trials of treatments for metabolic diseases in February, but that other info on the trials won't be available at that time.

You can see the company's slide presentation here.

Next StoryElon Musk released a photo of his latest rocket, and it already delivers on his promise of looking like liquid silver